The Implications of New Research Findings for the Management of Endometrial Cancer
Oncology Today with Dr Neil Love
00:00
MSI High Patients: A No Brainer?
Our lab has been filed to the FDA and has a PDU for day and action date in September. The degree of monitoring is different for an NRG study than it is when you have an in-house monitor double checking everything. In Europe where Ruby and Dostarlemab might have an overall survival advantage, that will be the preferred reimbursed agent based on the OS difference.
Transcript
Play full episode
